普莱柯：公司多款禽腺病毒系列联苗已获得新兽药注册证书并推向市场

Core Viewpoint - The company, Prike (603566), has made significant progress in the development and registration of various veterinary vaccines, indicating a strong pipeline of products ready for market introduction and clinical trials [1] Group 1: Product Development and Registration - Multiple avian adenovirus series vaccines have received new veterinary drug registration certificates and are now on the market [1] - Nearly 10 products, including the H5+H7 recombinant virus vector trivalent inactivated vaccine and the five-gene deletion strain of the pseudorabies live vaccine, have passed initial review or are in the re-examination stage for new veterinary drug registration [1] - The company has submitted new veterinary drug registration applications for products such as the infectious bronchitis (suspension culture technology) series vaccine and the canine quadrivalent and trivalent live vaccines [1] Group 2: Clinical Trials and Research - The porcine epidemic diarrhea genetic engineering subunit vaccine and the avian influenza (suspension culture technology) series vaccine are currently in clinical trial stages [1] - Several other vaccines and chemical drugs for livestock and pets are still in laboratory research stages [1]